|Articles|September 15, 2019
- BioPharm International-09-15-2019
- Volume 2019 eBook
- Issue 3
Is it Time to Update cGMPs?
Author(s)Agnes Shanley
Industry practice has changed radically over the past five decades. Can laws published in the 1960s still ensure pharmaceutical quality and safety today?
Advertisement
The biopharmaceutical industry has undergone major changes since GMPs were last updated in 1977. However, FDA says it has no plans for any major revisions of cGMPs. Industry experts argue, however, that changes are needed in Training and employee personal development, statistics and sampling, and process validation.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, September 2019
September 2019
Pages: 10–13
Citation
When referring to this article, please cite it as A. Shanley, “Is it Time to Update cGMPs?" BioPharm International Regulatory Sourcebook eBook (September 2019).
Articles in this issue
about 6 years ago
Global Pharmacopoeia Standards: Why Harmonization is Needed (eBook)about 6 years ago
Why Pharmacopoeia Compliance Is Difficult (eBook)about 6 years ago
Why Pharmacopoeia Compliance Is Necessary (eBook)about 6 years ago
What’s New in Regulations and Complianceabout 6 years ago
Quality Culture Drives Patient Confidence in Drug Productsabout 6 years ago
Biosimilar Quality Requirementsabout 6 years ago
Regulatory and Standard Setting Organizationsabout 6 years ago
Resources, Guidelines, and Guidance DocumentsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
